

Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin

June 16, 2016

Inventive Eye Supplement from Bausch + Lomb Offers Consumers Greater Ease and Convenience

LAVAL, Quebec, June 16, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, launched new PreserVision® AREDS 2 Formula + Multivitamin. PreserVision® is the #1 doctor-recommended eye vitamin brand specially formulated for people with moderate to advanced Age-Related Macular Degeneration.

The 2-in-1 formula helps make it simpler for consumers to take their supplements by reducing the number of pills taken each day and is the first leading brand to combine the National Eye Institute recommended AREDS2 nutrient formula with other essential vitamins and minerals typically found in daily multivitamins. PreserVision® AREDS 2 Formula + Multivitamin is beta carotene-free and contains a high level of Vitamin D to support the needs of older adults.

"We are proud that this new formula directly responds to consumer feedback and data and can create more convenience for those we serve," said Joseph C. Papa, chairman and chief executive officer. "The launch of PreserVision® AREDS 2 Formula + Multivitamin adds to Bausch + Lomb's long history of delivering innovation to eye health and underscores Valeant's commitment to inventive solutions that address consumers' healthcare needs."

The new PreserVision® AREDS 2 Formula + Multivitamin is now available in major retailers, including Walgreens, Rite Aid, Kroger and Amazon.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com

Forward-looking Statements

This press release contains forward-looking statements. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These

forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

PreserVision is a registered trademark of Bausch & Lomb Incorporated or its affiliates. AREDS and AREDS2 are registered trademarks of The U.S. Department of Health and Human Services (HHS).

Contact Information:

Laurie W. Little
laurie.little@valeant.com

or
Elif McDonald
elif.mcdonald@valeant.com

514-856-3855
877-281-6642 (toll free)

Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-launch-of-new-pr-eservision-areds-2-formula--multivitamin-300285751.html>

SOURCE Valeant Pharmaceuticals International, Inc.



Investor Inquiries

ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

Media inquiries

Corporate.communications@bauschhealth.com
908-569-3692

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**